SCHEMBL783497

SCHEMBL783497

COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)cc3)cc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.57
TEK Q02763 14/20 0.57
MET P08581 3/20 0.53
IGF1R P08069 2/20 0.53
MST1R Q04912 2/20 0.53
AURKA O14965 1/20 0.49
JAK2 O60674 1/20 0.49
RPS6KA5 O75582 1/20 0.49
ABL1 P00519 1/20 0.49
INSR P06213 1/20 0.49
LCK P06239 1/20 0.49
FES P07332 1/20 0.49
CSF1R P07333 1/20 0.49
LYN P07948 1/20 0.49
RET P07949 1/20 0.49
FGR P09769 1/20 0.49
KIT P10721 1/20 0.49
PIM1 P11309 1/20 0.49
FGFR1 P11362 1/20 0.49
SRC P12931 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565153 0.95 KDR (0.53) KDRTEKMETIGF1RMST1R
SCHEMBL199687 0.86 MET (0.51) KDRTEKMETIGF1RMST1R
SCHEMBL790668 0.77 MET (0.49) KDRTEKMETIGF1RMST1R
SCHEMBL12786992 0.75 MET (0.59) KDRTEKMETIGF1RMST1R
SCHEMBL198269 0.72 MET (0.73) KDRTEKMETIGF1RMST1R
SCHEMBL14444778 0.72 KDR (0.72) KDRTEKRAF1
SCHEMBL723553 0.72 MET (0.61) KDRTEKMETIGF1RMST1R
SCHEMBL14444771 0.72 KDR (0.78) KDRTEKRAF1
SCHEMBL15844536 0.71 MET (0.56) KDRTEKMETIGF1RMST1R
SCHEMBL2950401 0.71 MET (0.53) KDRTEKMETIGF1RMST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET KDR 200/4885TEK 147/4885MET 3/4885
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES HGF, HGFAC, MET KDR 304/4885TEK 157/4885MET 3/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET KDR 200/4885TEK 147/4885MET 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.